Studies show fewer than 25% of heart failure patients receive all four guideline-directed therapies at target doses. Clinit's GDMT tracker is designed to close that gap.
The Guideline-Practice Gap
The four pillars of heart failure with reduced ejection fraction (HFrEF) therapy — RAAS blockade, beta-blocker, MRA, and SGLT2 inhibitor — have Level A evidence for mortality benefit. Yet most real-world HF patients are under-treated, often because of simple inertia at the clinic visit level.
How the GDMT Tracker Works
The tracker appears as a dedicated section in the cardiology session tab for any patient with a heart failure diagnosis. It shows:
- ACEi / ARB / ARNI — Is the patient on one? Current dose vs target dose (e.g., sacubitril-valsartan 97/103 mg BD as target)
- Beta-blocker — Carvedilol/bisoprolol/metoprolol succinate. Current vs target dose
- MRA — Spironolactone/eplerenone. Current vs target
- SGLT2i — Dapagliflozin 10mg or empagliflozin 10mg. Present/absent
Gaps and sub-target doses are highlighted in amber. One click opens a pre-filled prescription for the next uptitration step.
Contraindication Flags
The tracker knows about the common contraindications: ACEi in bilateral renal artery stenosis, MRA when eGFR <30, SGLT2i in eGFR <20. These are checked against the patient's lab results and flagged before the prescription is opened.
Value for Patients
When a patient understands that each of their four heart medications has Level A evidence, adherence improves. Clinit's patient-facing GDMT summary can be printed or sent via the patient portal.
